Beam Therapeutics Inc.
US ˙ NasdaqGS ˙ US07373V1052

Introduktion

Denne side giver en omfattende analyse af den kendte insiderhandelshistorie for Carole Ho. Insidere er embedsmænd, direktører eller betydelige investorer i en virksomhed. Det er ulovligt for insidere at foretage handler i deres virksomheder baseret på specifik, ikke-offentlig information. Dette betyder ikke, at det er ulovligt for dem at handle i deres egne virksomheder. De skal dog rapportere alle handler til SEC via en formular 4. På trods af disse begrænsninger tyder akademisk forskning på, at insidere - generelt - har en tendens til at klare sig bedre end markedet i deres egne virksomheder.

Gennemsnitlig handelsrentabilitet

Den gennemsnitlige handelsrentabilitet er det gennemsnitlige afkast af alle køb på det åbne marked foretaget af insideren i de sidste tre år. For at beregne dette undersøger vi ethvert åbent marked, uplanlagte køb foretaget af insideren, eksklusive alle handler, der var markeret som en del af en 10b5-1-handelsplan. Vi beregner derefter den gennemsnitlige præstation for disse handler over 3, 6 og 12 måneder, idet vi tager et gennemsnit af hver af disse varigheder for at generere en endelig præstationsmåling for hver handel. Endelig tager vi et gennemsnit af alle præstationsmålingerne for at beregne en præstationsmåling for insideren. Denne liste inkluderer kun insidere, der har foretaget mindst tre handler i de sidste to år.

Hvis denne insiderhandelsrentabilitet er "N/A", så har insideren enten ikke foretaget nogen køb på det åbne marked i de sidste tre år, eller de handler, de har foretaget, er for nye til at beregne en pålidelig præstationsmåling.

Opdateringsfrekvens: Dagligt

Se listen over de mest profitable insiderhandlere.

Virksomheder med rapporterede insider-stillinger

SEC-registreringen viser, at Carole Ho har rapporteret besiddelser eller handler i følgende virksomheder:

Sikkerhed Titel Senest indberettede beholdninger
US:DNLI / Denali Therapeutics Inc. Chief Medical Officer 216.585
US:RPRX / Royalty Pharma plc Director 8.558
US:NGM / NGM Biopharmaceuticals, Inc. Director 24.222
US:BEAM / Beam Therapeutics Inc. Director 6.877
Sådan fortolkes diagrammerne

Følgende diagrammer viser aktieudviklingen for værdipapirer efter hver åben-marked, ikke-planlagt handel foretaget af Carole Ho. Ikke-planlagt handel er handler, der ikke blev foretaget som en del af en 10b5-1-handelsplan. Aktieudviklingen er kortlagt som den kumulative procentvise ændring i aktiekursen. For eksempel, hvis en insiderhandel blev foretaget den 1. januar 2019, vil diagrammet vise den daglige procentvise ændring af værdipapiret til i dag. Hvis aktiekursen skulle gå fra $10 til $15 i løbet af denne tid, ville den kumulative procentvise ændring i aktiekursen være 50%. En prisændring fra 10 USD til 20 USD ville være 100 %, og en ændring i prisen på 10 USD til 5 USD ville være -50 %.

I sidste ende forsøger vi at bestemme, hvor tæt insiderens handler korrelerer med merafkast (positive eller negative) i aktiekursen for at se, om insideren timing deres handler til at drage fordel af insiderinformation. Overvej situationen, hvor en insider gjorde dette. I denne situation ville vi forvente enten (a) positive afkast efter køb eller (b) negative afkast efter salg. I tilfælde af (a) vil KØB-diagrammet vise en række opadskrånende kurver, der indikerer positive afkast efter hver købstransaktion. I tilfælde af (b) vil SALE-diagrammet vise en række nedadgående kurver, der indikerer negative afkast efter hver salgstransaktion.

Dette alene er dog ikke nok til at drage konklusioner. Hvis for eksempel aktiekursen i selskabet var i en ikke-cyklisk stigning over mange år, så ville vi forvente, at alle efterkøbsgrundene var opadgående. Ligeledes ville ikke-cykliske fald over mange år resultere i nedadgående post-trade plots. Ingen af disse diagrammer tyder på insiderhandel.

Den stærkeste indikator ville være en situation, hvor aktiekursen var ekstremt cyklisk, og der var både positive signaler i KØB-diagrammet og negative plots på SALG-diagrammet. Denne situation ville i høj grad tyde på en insider, der havde timing af handler til deres økonomiske fordel.

Insiderkøb BEAM / Beam Therapeutics Inc. – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BEAM / Beam Therapeutics Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BEAM / Beam Therapeutics Inc. Insider Trades
Insidersalg BEAM / Beam Therapeutics Inc. – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BEAM / Beam Therapeutics Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

BEAM / Beam Therapeutics Inc. Insider Trades
Insiderkøb RPRX / Royalty Pharma plc – kortsigtet profitanalyse

I dette afsnit analyserer vi rentabiliteten af ethvert uplanlagt insiderkøb i åbent marked foretaget i BEAM / Beam Therapeutics Inc.. Denne analyse hjælper med at forstå, om insideren konsekvent genererer unormale afkast og er værd at følge. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste køb på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Maks
Pris kl
Maks
Maks
Fortjeneste ($)
Maks. afkast (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPRX / Royalty Pharma plc Insider Trades
Insidersalg RPRX / Royalty Pharma plc – kortsigtet tabsanalyse

I dette afsnit analyserer vi den kortsigtede undgåelse af tab af ethvert uplanlagt insidersalg på åbent marked, der foretages i BEAM / Beam Therapeutics Inc.. Et konsekvent mønster af tabsforebyggelse kan tyde på, at fremtidige salgstransaktioner kan forudsige prisfald. Denne analyse er for et år efter hver handel, og resultaterne er teoretiske .

Følgende tabel viser de seneste salg på det åbne marked, der ikke var en del af en automatisk handelsplan.

Handelsdato Ticker Insider Rapporteret
Aktier
Rapporteret
Pris
Justeret
Aktier
Justeret
Pris
Omkostningsgrundlag dage til
Min
Pris kl
Min
Max tab
Undgået ($)
Max tab
Undgået (%)
Der er ingen kendte uplanlagte åbne markedshandler for denne insider- og sikkerhedskombination

Justeret pris er den split-justerede pris. Adjusted Shares er de split-justerede aktier.

RPRX / Royalty Pharma plc Insider Trades
Insiderhandelshistorie

Denne tabel viser den komplette liste over insiderhandler foretaget af Carole Ho som oplyst til Securities Exchange Commission (SEC).

Fil dato Transdato Form Ticker Sikkerhed Kode 10b5-1 Aktier Resterende aktier Procent
Lave om
Del
Pris
Tran
Værdi
Tilbage
Værdi
2025-08-14 2025-08-13 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -806 216.585 -0,37 14,64 -11.800 3.170.804
2025-08-14 2025-08-12 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.937 217.391 -1,33 13,58 -39.884 2.952.170
2025-08-07 2025-08-05 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 44.655 220.328 25,42 0,68 30.365 149.823
2025-07-31 2025-07-31 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 5.806 8.558 210,97
2025-07-31 2025-07-31 4 RPRX Royalty Pharma plc
Class A Ordinary Shares
A - Award 2.752 2.752
2025-01-08 2025-01-07 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.907 175.673 -1,63 20,81 -60.495 3.655.755
2025-01-08 2025-01-06 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -12.255 178.580 -6,42 20,22 -247.796 3.610.888
2025-01-07 2025-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 54.180 190.835 39,65
2024-11-27 2024-11-25 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 17.845 136.655 15,02 0,68 12.135 92.925
2024-08-22 2024-08-21 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.907 118.810 -4,74 24,96 -147.439 2.965.498
2024-08-22 2024-08-21 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -14.098 124.717 -10,16 24,41 -344.132 3.044.342
2024-08-22 2024-08-20 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.453 138.815 -1,74 23,79 -58.357 3.302.409
2024-08-15 2024-08-13 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.337 141.268 -1,63 22,89 -53.494 3.233.625
2024-02-15 2024-02-14 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.405 143.605 -0,97 17,79 -24.995 2.554.733
2024-02-15 2024-02-13 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.784 145.010 -1,88 17,29 -48.135 2.507.223
2024-01-12 2024-01-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.668 147.794 -3,06 19,02 -88.785 2.811.042
2024-01-09 2024-01-05 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -9.972 198.777 -4,78 19,43 -193.756 3.862.237
2024-01-05 2024-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 53.720 162.434 49,41
2023-08-25 2023-08-23 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.522 182.809 -1,36 23,22 -58.561 4.244.825
2023-08-23 2023-08-21 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.478 185.331 -1,32 22,60 -56.003 4.188.481
2023-08-16 2023-08-14 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.768 182.809 -1,49 23,79 -65.851 4.349.026
2023-08-14 2023-08-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.857 185.577 -1,52 24,15 -68.997 4.481.685
2023-02-17 2023-02-15 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.476 182.809 -0,80 29,40 -43.394 5.374.585
2023-02-14 2023-02-13 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.548 184.285 -1,36 30,10 -76.695 5.546.978
2023-02-14 2023-02-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -818 179.365 -0,45 29,80 -24.376 5.345.077
2023-02-10 2023-02-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.521 180.183 -0,84 30,88 -46.968 5.564.051
2023-01-10 2023-01-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.459 177.454 -0,82 28,48 -41.552 5.053.890
2023-01-09 2023-01-06 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.451 178.913 -0,80 28,67 -41.600 5.129.436
2023-01-09 2023-01-05 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.636 180.364 -1,44 28,44 -74.968 5.129.552
2023-01-05 2023-01-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.913 175.500 -1,63 28,69 -83.574 5.035.095
2023-01-05 2023-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 41.120 138.967 42,02
2022-08-25 2022-08-23 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.424 170.663 -1,40 31,98 -77.520 5.457.803
2022-08-23 2022-08-19 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.576 173.087 -1,47 33,22 -85.575 5.749.950
2022-08-11 2022-08-09 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 22.500 110.597 25,54
2022-05-20 2022-05-18 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 24.222 24.222
2022-02-15 2022-02-11 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.918 170.663 -1,68 34,71 -101.284 5.923.713
2022-02-11 2022-02-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.423 166.112 -0,85 37,10 -52.791 6.162.539
2022-01-07 2022-01-05 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.845 163.285 -1,71 44,78 -127.399 7.311.902
2022-01-05 2022-01-03 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 93.000 93.000
2022-01-05 2022-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
A - Award 31.000 107.316 40,62
2021-12-08 2021-12-06 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.476 76.316 -1,90 42,52 -62.760 3.244.956
2021-08-25 2021-08-23 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -6.143 158.630 -3,73 48,91 -300.454 7.758.593
2021-08-23 2021-08-19 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.144 164.773 -0,69 49,91 -57.097 8.223.820
2021-08-23 2021-08-19 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.402 165.917 -0,84 49,31 -69.133 8.181.367
2021-06-14 2021-06-10 4 BEAM Beam Therapeutics Inc.
Stock Option (Right to Buy)
A - Award 6.877 6.877
2021-06-10 2021-06-08 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 19.619 19.619
2021-03-31 2021-03-29 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.822 162.319 -1,71 54,62 -154.126 8.865.215
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -68 165.141 -0,04 71,27 -4.846 11.769.599
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -125 165.209 -0,08 70,06 -8.758 11.575.369
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -208 165.334 -0,13 68,86 -14.324 11.385.726
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.320 165.542 -0,79 68,01 -89.772 11.258.346
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.173 166.862 -0,70 67,07 -78.670 11.190.934
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.871 168.035 -1,68 65,74 -188.725 11.045.781
2021-03-03 2021-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.327 170.906 -0,77 64,54 -85.646 11.030.444
2021-02-16 2021-02-11 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -400 172.233 -0,23 71,49 -28.594 12.312.248
2021-02-16 2021-02-11 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -2.756 172.633 -1,57 70,17 -193.377 12.112.967
2021-02-11 2021-02-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -100 167.921 -0,06 76,00 -7.600 12.761.996
2021-02-11 2021-02-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -364 168.021 -0,22 75,10 -27.337 12.618.713
2021-02-11 2021-02-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.006 168.385 -0,59 74,40 -74.847 12.528.012
2021-02-11 2021-02-07 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
M - Exercise -4.250 8.500 -33,33
2021-02-11 2021-02-07 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 4.250 169.391 2,57
2021-01-06 2021-01-04 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 90.000 90.000
2021-01-06 2021-01-04 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
A - Award 30.000 30.000
2020-11-30 2018-12-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -400 178.125 -0,22 19,16 -7.664 3.412.875
2020-11-30 2018-12-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.100 178.525 -8,74 18,43 -315.170 3.290.394
2020-11-30 2018-12-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 17.500 195.625 9,82 5,28 92.400 1.032.900
2020-11-30 2018-11-15 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.500 178.125 -8,95 18,07 -316.157 3.218.024
2020-11-30 2018-11-15 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 12.235 195.625 6,67 5,28 64.601 1.032.900
2020-11-30 2019-01-04 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.450 178.125 -2,44 20,03 -89.134 3.567.844
2020-11-30 2019-01-04 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.500 182.575 -0,81 19,30 -28.950 3.523.698
2020-11-30 2019-01-04 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.950 184.075 3,34 5,28 31.416 971.916
2020-11-30 2019-01-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.775 178.125 -3,14 18,90 -109.148 3.366.562
2020-11-30 2019-01-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 183.900 3,24 5,28 30.492 970.992
2020-11-30 2019-01-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -900 178.125 -0,50 20,24 -18.216 3.605.250
2020-11-30 2019-01-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.875 179.025 -2,65 19,43 -94.721 3.478.456
2020-11-30 2019-01-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 183.900 3,24 5,28 30.492 970.992
2020-10-13 2020-10-09 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -30.000 38.240 -43,96
2020-10-13 2020-10-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -19.535 166.617 -10,49 41,51 -810.898 6.916.272
2020-10-13 2020-10-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -10.465 186.152 -5,32 40,68 -425.716 7.572.663
2020-10-13 2020-10-09 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 30.000 196.617 18,01 5,28 158.400 1.038.138
2020-10-13 2020-10-08 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -9.886 68.240 -12,65
2020-10-13 2020-10-08 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -13.020 44.035 -22,82
2020-10-13 2020-10-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -22.906 166.617 -12,09 40,12 -918.989 6.684.674
2020-10-13 2020-10-08 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 22.906 189.523 13,75 5,28 120.944 1.000.681
2020-09-14 2020-09-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.689 165.141 -2,19 31,00 -114.359 5.119.371
2020-08-24 2020-08-21 4 DNLI Denali Therapeutics Inc.
Common Stock
F - Taxes -1.954 6.511 -23,08 32,88 -64.248 214.082
2020-08-24 2020-08-20 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
M - Exercise -5.643 0 -100,00
2020-08-24 2020-08-20 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.643 8.465 199,96
2020-08-20 2020-08-18 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
A - Award 20.000 20.000
2020-06-09 3 NGM NGM BIOPHARMACEUTICALS INC
Common Stock
0
2020-06-09 2020-06-05 4 NGM NGM BIOPHARMACEUTICALS INC
Stock Option (Right to Buy)
A - Award 39.515 39.515
2020-04-01 2020-03-30 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale -1.428 2.822 -33,60 19,48 -27.817 54.973
2020-04-01 2020-02-07 4/A DNLI Denali Therapeutics Inc.
Restricted Stock Units
M - Exercise -4.250 12.750 -25,00
2020-04-01 2020-02-07 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 4.250 4.250
2020-02-12 2020-02-10 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 142.000 142.000
2020-02-12 2020-02-10 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
A - Award 29.874 29.874
2019-12-23 2019-12-23 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.464 0 -100,00 20,01 -69.315
2019-12-23 2019-12-20 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -860 3.464 -19,89 20,00 -17.200 69.280
2019-12-23 2019-12-19 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.566 4.324 -37,24 20,00 -51.320 86.480
2019-08-22 2019-08-21 4 DNLI Denali Therapeutics Inc.
Common Stock
F - Taxes -2.834 49.684 -5,40 18,59 -52.671 923.392
2019-08-22 2019-08-20 4 DNLI Denali Therapeutics Inc.
Restricted Stock Unites
M - Exercise -5.643 5.643 -50,00
2019-08-22 2019-08-20 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.643 52.518 12,04
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -3.907 78.126 -4,76
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -2.604 92.565 -2,74
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.100 79.934 -1,36 20,88 -22.968 1.669.022
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -9.889 81.034 -10,88 20,21 -199.857 1.637.697
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.907 4.081 -48,91 20,55 -80.289 83.865
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 3.907 7.988 95,74 5,28 20.629 42.177
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.604 4.081 -38,95 19,93 -51.898 81.334
2019-07-10 2019-07-08 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 2.604 6.685 63,81 5,28 13.749 35.297
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -3.906 82.033 -4,55
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -711 95.169 -0,74
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -12.883 90.923 -12,41 18,78 -241.943 1.707.534
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.906 0 -100,00 18,81 -73.472
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 3.906 3.906 5,28 20.624 20.624
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -711 0 -100,00 18,62 -13.239
2019-06-12 2019-06-10 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 711 711 5,28 3.754 3.754
2019-05-10 2019-05-10 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -2.546 85.939 -2,88
2019-05-10 2019-05-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.316 103.806 -3,10 22,16 -73.483 2.300.341
2019-05-10 2019-05-10 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.546 0 -100,00 22,17 -56.445
2019-05-10 2019-05-10 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 2.546 2.546 5,28 13.443 13.443
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -2.653 88.485 -2,91
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -200 107.122 -0,19 23,60 -4.720 2.528.079
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.010 107.322 -2,73 22,83 -68.718 2.450.161
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -200 0 -100,00 23,58 -4.716
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.453 200 -92,46 22,86 -56.076 4.572
2019-05-10 2019-05-09 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 2.653 2.653 5,28 14.008 14.008
2019-05-10 2019-05-08 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -2.613 91.138 -2,79
2019-05-10 2019-05-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.162 110.332 -2,79 23,51 -74.339 2.593.905
2019-05-10 2019-05-08 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.613 0 -100,00 23,50 -61.406
2019-05-10 2019-05-08 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 2.613 2.613 5,28 13.797 13.797
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.862 93.751 -5,88
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -900 123.082 -0,73 26,79 -24.111 3.297.367
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -8.688 123.982 -6,55 26,29 -228.408 3.259.487
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -600 0 -100,00 26,81 -16.086
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.262 600 -89,76 26,27 -138.233 15.762
2019-05-10 2019-04-03 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.862 5.862 5,28 30.951 30.951
2019-05-10 2019-04-02 4/A DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -6.242 99.613 -5,90
2019-05-10 2019-04-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -9.445 132.670 -6,65 25,29 -238.864 3.355.224
2019-05-10 2019-04-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.442 0 -100,00 25,15 -86.566
2019-05-10 2019-04-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.800 3.442 -44,86 24,51 -68.628 84.363
2019-05-10 2019-04-02 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise X 6.242 6.242 5,28 32.958 32.958
2019-05-10 2019-04-01 4/A DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.775 105.855 -5,17
2019-05-10 2019-04-01 4/A DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.775 0 -100,00 23,91 -138.080
2019-05-10 2019-04-01 4/A DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 5.775 5,28 30.492 30.492
2019-04-08 2019-04-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.433 113.494 -1,25 27,00 -38.691 3.064.338
2019-04-08 2019-04-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -8.155 114.927 -6,63 26,24 -213.987 3.015.684
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.862 93.858 -5,88
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -900 123.082 -0,73 26,79 -24.111 3.297.367
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -8.688 123.982 -6,55 26,29 -228.408 3.259.487
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -600 0 -100,00 26,81 -16.086
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.262 600 -89,76 26,27 -138.233 15.762
2019-04-03 2019-04-03 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise -5.862 5.862 -50,00 5,28 -30.951 30.951
2019-04-03 2019-04-02 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -6.135 99.720 -5,80
2019-04-03 2019-04-02 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -9.445 132.670 -6,65 25,29 -238.864 3.355.224
2019-04-03 2019-04-02 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.335 0 -100,00 25,15 -83.875
2019-04-03 2019-04-02 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.800 3.335 -45,64 24,51 -68.628 81.741
2019-04-03 2019-04-02 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 6.135 6.135 5,28 32.393 32.393
2019-04-03 2019-04-01 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.775 105.855 -5,17
2019-04-03 2019-04-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.775 0 -100,00 23,91 -138.080
2019-04-03 2019-04-01 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 5.775 5,28 30.492 30.492
2019-03-18 2019-03-14 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -500 111.630 -0,45
2019-03-18 2019-03-14 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -500 0 -100,00 25,01 -12.505
2019-03-18 2019-03-14 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -500 0 -100,00 25,01 -12.505
2019-03-18 2019-03-14 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 500 500 5,28 2.640 2.640
2019-03-05 2019-03-05 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.862 112.130 -4,97
2019-03-05 2019-03-05 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.862 0 -100,00 21,96 -128.730
2019-03-05 2019-03-05 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.862 5.862 5,28 30.951 30.951
2019-03-05 2019-03-04 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.863 117.992 -4,73
2019-03-05 2019-03-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.600 0 -100,00 22,84 -36.544
2019-03-05 2019-03-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.263 1.600 -72,71 21,87 -93.232 34.992
2019-03-05 2019-03-04 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.863 5.863 5,28 30.957 30.957
2019-03-05 2019-03-01 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.775 123.855 -4,45
2019-03-05 2019-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.951 0 -100,00 22,92 -44.717
2019-03-05 2019-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.824 1.951 -66,22 22,17 -84.778 43.254
2019-03-05 2019-03-01 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 5.775 5,28 30.492 30.492
2019-02-11 2019-02-07 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 136.000 136.000
2019-02-11 2019-02-07 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
A - Award 17.000 17.000
2019-02-05 2019-02-05 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -7.856 129.630 -5,71
2019-02-05 2019-02-05 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -7.856 0 -100,00 18,83 -147.928
2019-02-05 2019-02-05 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 7.856 7.856 5,28 41.480 41.480
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -3.139 137.486 -2,23
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -730 95.880 -0,76
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -769 0 -100,00 19,11 -14.696
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -3.100 769 -80,12 18,49 -57.319 14.219
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 3.139 3.869 430,00 5,28 16.574 20.428
2019-02-05 2019-02-04 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 730 730 5,28 3.854 3.854
2019-02-05 2019-02-01 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.775 96.610 -5,64
2019-02-05 2019-02-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -5.775 0 -100,00 18,64 -107.646
2019-02-05 2019-02-01 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 5.775 5,28 30.492 30.492
2019-01-04 2019-01-04 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.950 102.385 -5,49
2019-01-04 2019-01-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.450 2.777 -61,57 20,03 -89.134 55.623
2019-01-04 2019-01-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -1.500 7.227 -17,19 19,30 -28.950 139.481
2019-01-04 2019-01-04 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.950 8.727 214,26 5,28 31.416 46.079
2019-01-04 2019-01-03 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
M - Exercise -5.775 108.335 -5,06
2019-01-04 2019-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -2.777 2.777 -50,00 18,90 -52.485 52.485
2019-01-04 2019-01-03 4 DNLI Denali Therapeutics Inc.
Common Stock
M - Exercise 5.775 8.552 207,96 5,28 30.492 45.155
2019-01-04 2019-01-02 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -900 142.615 -0,63 20,24 -18.216 2.886.528
2019-01-04 2019-01-02 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -4.875 143.515 -3,29 19,43 -94.721 2.788.496
2018-12-06 2018-12-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -400 148.390 -0,27 19,16 -7.664 2.843.152
2018-12-06 2018-12-03 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.100 148.790 -10,31 18,43 -315.170 2.742.348
2018-11-19 2018-11-15 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.500 165.890 -9,54 18,07 -316.157 2.996.985
2018-10-03 2018-10-01 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.500 183.390 -8,71 21,72 -380.100 3.983.231
2018-09-06 2018-09-04 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.500 200.890 -8,01 19,05 -333.375 3.826.954
2018-08-31 2018-08-29 4 DNLI Denali Therapeutics Inc.
Common Stock
S - Sale X -17.500 218.390 -7,42 18,04 -315.700 3.939.756
2018-08-22 2018-08-20 4 DNLI Denali Therapeutics Inc.
Restricted Stock Units
A - Award 11.286 11.286
2018-02-28 2018-02-26 4 DNLI Denali Therapeutics Inc.
Stock Option (right to buy)
A - Award 180.000 180.000
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
354.640
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
543.655
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
332.765
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
354.640
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
543.655
2017-12-07 3 DNLI Denali Therapeutics Inc.
Common Stock
332.765
P
Åbent marked eller privat køb af ikke-afledte eller afledte værdipapirer
S
Åbent marked eller privat salg af ikke-afledte eller afledte værdipapirer
A
Tildeling, tildeling eller anden erhvervelse af værdipapirer fra virksomheden (såsom en option)
C
Konvertering af derivat
D
Salg eller overførsel af værdipapirer tilbage til virksomheden
F
Betaling af udnyttelseskurs eller skatteforpligtelse ved brug af en del af værdipapirer modtaget fra selskabet
G
Gave af værdipapirer af eller til insideren
K
Aktieswaps og lignende sikringstransaktioner
M
Udnyttelse eller konvertering af afledt værdipapir modtaget fra virksomheden (såsom en option)
V
En transaktion rapporteret frivilligt på formular 4
J
Andet (ledsaget af en fodnote, der beskriver transaktionen)